The mammalian or mechanistic target of rapamycin (mTOR) pathway plays a crucial role in
regulation of cell survival, metabolism, growth and protein synthesis in response to upstream …

Novel drugs, drug sequences and combinations have improved the outcome of prostate
cancer in recent years. The latest approvals include abiraterone acetate, enzalutamide and …

Prostate cancer is a leading cause of cancer-related death in men worldwide. Aberrant
signaling in the androgen pathway is critical in the development and progression of prostate …

Androgen receptor (AR) is a validated drug target for prostate cancer based on its role in
proliferation, survival, and metastases of prostate cancer cells. Unfortunately, despite recent …

Prostate cancer (PCa) is a common and fatal type of cancer in men. Metastatic PCa (mPCa)
is a major factor contributing to its lethality, although the mechanisms remain poorly …

Androgen receptor (AR) signaling reprograms cellular metabolism to support prostate
cancer (PCa) growth and survival. Another key regulator of cellular metabolism is mTOR, a …

With increases in the mortality rate and number of patients with prostate cancer (PCa), PCa,
particularly the advanced and metastatic disease, has been the focus of a number of studies …

Alzheimer's disease (AD) and cancer are among the leading causes of human death around
the world. While neurodegeneration is the main feature of AD, the most important …

Abstract Purpose of Review Despite significant progress, patients with metastatic prostate
cancer continue to have poor prognosis. Immunotherapy has revolutionized cancer care for …

Background Prostate cancer is one of leading causes of cancer death among men
worldwide. Androgen deprivation therapy is a central part of the prostate cancer treatment …